I'm LongbridgeAI, I can summarize articles.Tarsus Pharmaceuticals agreed to acquire privately held iRenix Medical for approximately USD 75 million upfront, split between cash and stock. The deal includes up to USD 490 million in potential milestone payments. The acquisition adds late-stage ocular antiseptic IRX-101, which showed positive Phase 2b/3 data. Tarsus plans to start Phase 3 trials in the first half of 2027, with results expected in 2028.
- Tarsus Pharmaceuticals agreed to acquire privately held iRenix Medical, adding late-stage ocular antiseptic candidate IRX-101 for intravitreal procedures. * Consideration totals about USD 75 million upfront, split evenly between cash and Tarsus common stock. * Deal includes up to USD 490 million in potential approval and commercial milestone payments. * IRX-101 posted positive Phase 2b/3 data versus povidone-iodine on post-procedural pain and corneal staining endpoints. * Phase 3 start targeted for H1 2027, with results expected in 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607081605PRIMZONEFULLFEED9759224) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)